COMBI-I长期总生存:Spartalizumab联合达拉非尼与曲美替尼治疗BRAF V600突变晚期黑色素瘤
COMBI-I试验最终分析报告至少5年扩展随访的总生存(OS)结果。sparta-DabTram组(n=267)中位OS为61.5个月(95%CI 41.6至不可评估),安慰剂-DabTram组(n=265)为41.6个月(95%CI 30.6至56.9),HR 0.760(95%CI 0.598至0.966)。安全性特征与已知一致,sparta-DabTram组发热和≥3级治疗相关不良事件发生率更高。
要点
- sparta-DabTram组中位OS 61.5个月,安慰剂-DabTram组41.6个月,HR 0.760。
- sparta-DabTram组发热发生率65.9%,对照组46.2%。
- sparta-DabTram组≥3级TRAE发生率57.3%,对照组36.7%。
核心结论
- 在BRAF V600突变转移性黑色素瘤患者中,sparta-DabTram联合方案较达拉非尼联合曲美替尼单用似可改善总生存。
研究设计与样本
- COMBI-I试验(NCT02967692)比较sparta-DabTram(n=267)与安慰剂-DabTram(n=265)治疗BRAF V600突变不可切除或转移性黑色素瘤。
- 本次为最终分析,报告至少5年扩展随访期间的总生存(OS)结果。
主要发现
- 试验结束时(2024年8月21日),中位随访时间为76.9个月(范围73.7至83.3个月)。
- sparta-DabTram组中位OS为61.5个月(95%CI 41.6至不可评估),安慰剂-DabTram组为41.6个月(95%CI 30.6至56.9)。
- OS的风险比为0.760(95%CI 0.598至0.966)。
- 安全性发现与sparta-DabTram已知安全性特征一致。
关键数值与推荐
- 最常见的治疗相关不良事件(TRAE)为发热,sparta-DabTram组与安慰剂-DabTram组分别为65.9%与46.2%。
- ≥3级TRAE在两组的报告率分别为57.3%与36.7%。
临床怎么用
- 对于BRAF V600突变转移性黑色素瘤,sparta-DabTram联合方案在长期随访中显示OS获益趋势,但需权衡更高的发热和≥3级TRAE发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COMBI-I trial (ClinicalTrials.gov identifier: NCT02967692) evaluating spartalizumab plus dabrafenib and trametinib (sparta-DabTram, n = 267) versus placebo plus dabrafenib and trametinib (placebo-DabTram, n = 265) for BRAF V600-mutant unresectable or metastatic melanoma failed to reach its primary end point of progression-free survival at 24 months. This final analysis reports overall survival (OS) during at least 5 years of extended follow-up. At the end of the trial (August 21, 2024), the median duration of follow-up was 76.9 months (range, 73.7-83.3 months). The median OS was 61.5 months (95% CI, 41.6 to not evaluable) for the sparta-DabTram arm and 41.6 months (95% CI, 30.6 to 56.9) for the placebo-DabTram arm (hazard ratio, 0.760 [95% CI, 0.598 to 0.966]). The safety findings were consistent with the known safety profile for sparta-DabTram. The most common treatment-related adverse event (TRAE) was pyrexia (65.9% v 46.2%, respectively, in the two study arms). Grade ≥3 TRAEs were reported in 57.3% and 36.7% of patients in the two arms, respectively. The combination of sparta-DabTram appears to improve OS compared with dabrafenib and trametinib alone in patients with BRAF V600-mutant metastatic melanoma.
引用
- Ribas A, Robert C, Schadendorf D, et al. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma. J Clin Oncol. 2026. PMID: 42585631. doi:10.1200/JCO-26-00528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。